News

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

2012

  • Dec 14, 2012 Notice concerning adoption of
    International Financial Reporting Standards (IFRS)
    [PDF 53KB]
  • Dec 13, 2012 Organizational and Personnel Changes
    [PDF 146KB]
  • Nov 28, 2012 Chugai Pharma Manufacturing to Conclude an Agreement with Fujieda City
    to Offer Help During Times of Disaster
    [PDF 349KB]
  • Nov 27, 2012 Co-Development and Co-Marketing Agreement for
    the Glycoengineered Type II Anti-CD20 Monoclonal Antibody,
    “GA101 (obinutuzumab)”
    [PDF 17KB]
  • Nov 26, 2012 Notice Concerning the Passing Away
    of a Chugai Pharmaceutical Director
    [PDF 162KB]
  • Nov 12, 2012 ADACTA Study Showed ACTEMRA Improved Signs and Symptoms
    of Rheumatoid Arthritis Significantly More Than Adalimumab as a
    Single-Agent Therapy
    [PDF 214KB]
  • Nov 05, 2012 Eli Lilly Japan and Chugai to Terminate
    Co-Marketing Agreement of “EVISTA® tablet 60mg,”
    a Treatment for Osteoporosis in Postmenopausal Women
    [PDF 144KB]
  • Nov 01, 2012 Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2012-2013 Season
    [PDF 133KB]
  • Oct 26, 2012 License Agreement of SGLT2 Inhibitor “CSG452” in Japan
    [PDF 96KB]
  • Oct 19, 2012 Chugai Presents an Anti-Cancer Charity
    WAHAHA HONPO Special Live Show
    [PDF 200KB]
  • Oct 19, 2012 Chugai Succeeds in Establishing Stable Cell Lines of Cancer
    Stem Cell for the First Time
    - A step forward in elucidating the mechanisms of recurrence/metastasis and drug
    resistance of cancer and in the development of a new therapeutic agent -
    [PDF 231KB]
  • Oct 16, 2012 F. Hoffmann-La Roche Announces Third Quarter Sales 2012
    [PDF 22KB]
  • Oct 15, 2012 FDA Approves Expanded Indication for ACTEMRA®
    in Rheumatoid Arthritis
    [PDF 187KB]
  • Oct 05, 2012 Anti-Cancer Agent “Avastin®,”
    Application for Approval of Additional Indication of Ovarian Cancer
    [PDF 177KB]
  • Oct 01, 2012 Novel Concept for Treatment of Hemophilia A
    Published in Nature Medicine
    -Bispecific antibody substitutes for the function of blood coagulation factor VIII-
    [PDF 189KB]
  • Sep 27, 2012 Contribution of Para-transit Vehicles to Welfare Services
    [PDF 224KB]
  • Sep 19, 2012 Anti-Cancer Agent “Avastin®,”
    Application for Approval of Additional Indication of
    Recurrent Glioblastoma
    [PDF 177KB]
  • Aug 31, 2012 Resignation of a Director
    [PDF 172KB]
  • Aug 10, 2012 Synthetic Antibacterial Agent, Bactramin®
    Approved for Additional Indication of
    “Treatment and Prevention of Pneumocystis Pneumonia”
    [PDF 117KB]
  • Jul 27, 2012 Roche Reports Second Positive Study of RoACTEMRA Given by
    Subcutaneous Injection to Patients with Rheumatoid Arthritis
    [PDF 213KB]
  • Jul 26, 2012 F. Hoffmann-La Roche Announces Second Quarter Sales 2012
    [PDF 21KB]
  • Jul 18, 2012 New Drug Application Filed for Ibandronate Sodium Hydrate Injection,
    Bisphosphonate Antiresorptive Agent
    [PDF 19KB]
  • Jul 17, 2012 Opening of Chugai’s Research Subsidiary
    “Chugai Pharmabody Research Pte. Ltd.” in Singapore
    [PDF 199KB]
  • Jun 26, 2012 Anti-Cancer Agent “Tarceva®,”
    Application for Approval of Additional Indication of
    Non-Small Cell Lung Cancer (First Line Therapy)
    [PDF 170KB]
  • Jun 07, 2012 Launch of an Orphan Drug, “Pulmozyme®,”
    a Recombinant Human Deoxyribonuclease I (rhDNase)
    [PDF 366KB]
  • Jun 06, 2012 Roche’s RoACTEMRA
    Improved Rheumatoid Arthritis Signs and Symptoms
    Significantly More than Adalimumab as Single-Agent Therapy
    [PDF 194KB]
  • May 25, 2012 New Drug Application Filed for Anti-Cancer Agent “Pertuzumab”
    for the Treatment of HER2-Positive Metastatic or Recurrent
    Breast Cancer
    [PDF 189KB]
  • May 11, 2012 Chugai Renews its “Human Body System” Website
    -Now easier to understand with abundant illustrations and captions-
    [PDF 162KB]
  • May 10, 2012 Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
    [PDF 50KB]
  • May 07, 2012 Roche Reports Positive Study of RoACTEMRA
    Given by Subcutaneous Injection
    [PDF 244KB]
  • Apr 24, 2012 Issuance of Stock Options (Stock Acquisition Rights)
    [PDF 79KB]
  • Apr 12, 2012 F. Hoffmann-La Roche Announces First Quarter Sales 2012
    [PDF 21KB]
  • Apr 11, 2012 Chugai Establishes Endowed Course at Keio University
    – “Health” related issues to be extracted and searched for solutions –
    [PDF 150KB]
  • Mar 30, 2012 Approval of an Orphan Drug, “Pulmozyme®,”
    a Recombinant Human Deoxyribonuclease I (rhDNase)
    [PDF 243KB]
  • Mar 02, 2012 Roche’s RoACTEMRA Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
    [PDF 249KB]
  • Feb 21, 2012 FDA Accepts Supplemental Biologics License Application Submitted for
    ACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,
    Regarding Adult Rheumatoid Arthritis Indication
    [PDF 181KB]
  • Feb 13, 2012 Synthetic Antibacterial Agent, Bactramin®
    Filed for Additional Indication By
    “Application Based on Evidence in the Public Domain”
    [PDF 94KB]
  • Feb 07, 2012 Anti-Cancer Agent, Tarceva®
    Condition for Approval (All Patients Surveillance) Partially Removed in Japan for
    “Nonresectable Recurrent and Advanced Non-small Cell Lung Cancer
    which is Aggravated Following Chemotherapy”
    [PDF 173KB]
  • Feb 01, 2012 Notice of Changes to Representative Directors
    [PDF 50KB]
  • Feb 01, 2012 Personnel Changes
    [PDF 54KB]
  • Feb 01, 2012 Organizational and Personnel Changes
    [PDF 151KB]
  • Feb 01, 2012 Notice of Partial Amendments to the Articles of Incorporation
    [PDF 50KB]
  • Feb 01, 2012 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2011
    [PDF 40KB]
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top